Detailed Information on Publication Record
2023
Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future
ŘIHÁČKOVÁ, Eva, Michal ŘIHÁČEK, Mária VYSKOČILOVÁ, Dalibor VALÍK, Lubomír ELBL et. al.Basic information
Original name
Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future
Authors
ŘIHÁČKOVÁ, Eva (203 Czech Republic, belonging to the institution), Michal ŘIHÁČEK (203 Czech Republic, belonging to the institution), Mária VYSKOČILOVÁ (703 Slovakia, belonging to the institution), Dalibor VALÍK (203 Czech Republic, belonging to the institution) and Lubomír ELBL (203 Czech Republic, belonging to the institution)
Edition
Frontiers in Cardiovascular Medicine, Lausanne, Frontiers, 2023, 2297-055X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30201 Cardiac and Cardiovascular systems
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 3.600 in 2022
RIV identification code
RIV/00216224:14110/23:00131614
Organization unit
Faculty of Medicine
UT WoS
001064769300001
Keywords in English
lymphoma; cardiotoxicity; chemotherapy; modern treatment; prevention; cardiac adverse events
Tags
International impact, Reviewed
Změněno: 17/1/2024 11:56, Mgr. Tereza Miškechová
Abstract
V originále
Treatment of malignant lymphoma has for years been represented by many cardiotoxic agents especially anthracyclines, cyclophosphamide, and thoracic irradiation. Although they are in clinical practice for decades, the precise mechanism of cardiotoxicity and effective prevention is still part of the research. At this article we discuss most routinely used anti-cancer drugs in chemotherapeutic regiments for malignant lymphoma with the focus on novel insight on molecular mechanisms of cardiotoxicity. Understanding toxicity at molecular levels may unveil possible targets of cardioprotective supportive therapy or optimization of current therapeutic protocols. Additionally, we review novel specific targeted therapy and its challenges in cardio-oncology.
Links
| 90249, large research infrastructures |
|